Celecoxib Cuts Opioid Use Nearly in Half After Throat Surgery—Without Increasing Pain
Highlights
Postoperative celecoxib administration significantly reduced opioid consumption by 44% in patients undergoing benign oropharyngeal surgery. Pain scores remained comparable between celecoxib and non-celecoxib cohorts across all measured time points. These findings support the integration of celecoxib into multimodal pain management protocols to minimize opioid exposure. Larger randomized trials are needed to confirm these preliminary observations.
Background: The Opioid Challenge in Oropharyngeal Surgery
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.